Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy, safety and pharmacokinetics of once or twice daily bilastine (10 or 20 mg) compared with placebo given orally in the treatment of the symptoms of seasonal allergic rhino-conjunctivitis with allergy to mountain cedar pollen.

Next Previous
Trial Profile

A multi-center randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy, safety and pharmacokinetics of once or twice daily bilastine (10 or 20 mg) compared with placebo given orally in the treatment of the symptoms of seasonal allergic rhino-conjunctivitis with allergy to mountain cedar pollen.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bilastine (Primary)
  • Indications Rhinoconjunctivitis
  • Focus Therapeutic Use
  • Sponsors FAES Farma

Most Recent Events

  • 09 Jan 2009 Planned number of patients changed from 750 to 805 as reported by ClinicalTrials.gov.
  • 09 Jan 2009 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.
  • 09 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top